Fresh analysis reveals that individuals who come off blockbuster weight-loss injections like semaglutide or tirzepatide tend to recover shed pounds at a significantly accelerated pace than those who halt traditional diet and exercise regimens.
Research printed in a prominent health publication demonstrates that while obese people frequently drop about a fifth of their body weight while undergoing treatment, the mass is regained at an average rate of nearly a kilo each month after stopping.
"Users buying these treatments need to be informed of the risk of rapid weight regain when the treatment is stopped," stated researcher Dr. Susan Jebb.
This pace of recovery implies a return to starting mass within about a year and a half.
Comparing Treatments
The study, which reviewed dozens of trials involving thousands of patients, compared the outcomes of GLP-1 agonists with conventional dieting.
The team emphasize that people who lose weight through diet and exercise usually see a slower creep back—perhaps 0.1 kg a month—post-intervention.
Explaining the Fast Regain
Nutrition scientists suggest the mechanism of the injections is key to understanding the heightened rebound.
GLP-1 drugs mimic a natural hormone called glucagon-like peptide-1, which controls feelings of fullness.
"Sustained high doses of the hormone levels far above than the body's typical production may cause the body to generate a reduced amount of its own natural GLP-1, and may also diminish responsiveness to its effects," explained Dr. Adam Collins, a dietetics expert.
"Stopping of this hormone supplement leads to hunger is unsuppressed, making binge eating a significant risk."
A Lifelong Condition?
The NHS suggest the injections for individuals with weight-linked medical conditions, accompanied by recommended lifestyle changes.
A number of clinicians say that, given the likelihood of weight regain, the therapy should be considered long-term.
This perspective is reinforced by pharmaceutical companies, who note that the findings "underscore the persistent character of obesity," comparing it to managing conditions like diabetes.
User Experiences
Individuals who have stopped the medication explain a sudden return of cravings.
"It was like a switch that goes on and you become starving," recalled one woman.
This difficulty is compounded if individuals have not established sustainable lifestyle or habit modifications during therapy.
Growing Adoption
Figures suggest that millions of people in the UK have used weight-loss jabs in the past year, with desire being substantial.
- Use is more common among females than males.
- The middle-aged demographic shows the greatest level of interest.
- Many access the drugs through private healthcare rather than the NHS.
In conclusion, experts caution that while GLP-1 drugs are effective agents for shedding pounds, they are not a permanent solution and maintained weight loss hinges on integrated behavioural support.
